Your browser doesn't support javascript.
loading
Activation of Tumor-Cell STING Primes NK-Cell Therapy.
Knelson, Erik H; Ivanova, Elena V; Tarannum, Mubin; Campisi, Marco; Lizotte, Patrick H; Booker, Matthew A; Ozgenc, Ismail; Noureddine, Moataz; Meisenheimer, Brittany; Chen, Minyue; Piel, Brandon; Spicer, Nathaniel; Obua, Bonje; Messier, Cameron M; Shannon, Erin; Mahadevan, Navin R; Tani, Tetsuo; Schol, Pieter J; Lee-Hassett, Anna M; Zlota, Ari; Vo, Ha V; Ha, Minh; Bertram, Arrien A; Han, Saemi; Thai, Tran C; Gustafson, Corinne E; Venugopal, Kartika; Haggerty, Timothy J; Albertson, Thomas P; Hartley, Antja-Voy; Eser, Pinar O; Li, Ze-Hua; Cañadas, Israel; Vivero, Marina; De Rienzo, Assunta; Richards, William G; Abu-Yousif, Adnan O; Appleman, Vicky A; Gregory, Richard C; Parent, Alexander; Lineberry, Neil; Smith, Eric L; Jänne, Pasi A; Miret, Juan J; Tolstorukov, Michael Y; Romee, Rizwan; Paweletz, Cloud P; Bueno, Raphael; Barbie, David A.
Afiliação
  • Knelson EH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Ivanova EV; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Tarannum M; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Campisi M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Lizotte PH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Booker MA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Ozgenc I; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Noureddine M; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Meisenheimer B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Chen M; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Piel B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Spicer N; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Obua B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Messier CM; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Shannon E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Mahadevan NR; Department of Immunology, Harvard Medical School, Boston, Massachusetts.
  • Tani T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Schol PJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Lee-Hassett AM; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Zlota A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Vo HV; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Ha M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Bertram AA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Han S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Thai TC; Graduate Medical Sciences Program, Boston University School of Medicine, Boston, Massachusetts.
  • Gustafson CE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Venugopal K; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Haggerty TJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Albertson TP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Hartley AV; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Eser PO; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Li ZH; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Cañadas I; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Vivero M; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • De Rienzo A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Richards WG; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Abu-Yousif AO; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Appleman VA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Gregory RC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Parent A; Deparment of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.
  • Lineberry N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Smith EL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Jänne PA; Deparment of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.
  • Miret JJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Tolstorukov MY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Romee R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Paweletz CP; Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Bueno R; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Barbie DA; Deparment of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.
Cancer Immunol Res ; 10(8): 947-961, 2022 08 03.
Article em En | MEDLINE | ID: mdl-35678717
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células Matadoras Naturais / Imunoterapia Adotiva / Mesotelioma Maligno / Proteínas de Membrana Limite: Humans Idioma: En Revista: Cancer Immunol Res Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células Matadoras Naturais / Imunoterapia Adotiva / Mesotelioma Maligno / Proteínas de Membrana Limite: Humans Idioma: En Revista: Cancer Immunol Res Ano de publicação: 2022 Tipo de documento: Article